Related Experiment Videos
Node-negative breast cancer: prognostic subgroups defined by tumor size and flow cytometry.
S M O'Reilly1, R S Camplejohn, D M Barnes
1Imperial Cancer Research Fund Clinical Oncology Unit, Guy's Hospital, London, United Kingdom.
Summary
Tumor size and S-phase fraction (SPF) help predict breast cancer relapse risk. Small tumors (<1.0 cm) have good outcomes, while larger tumors with high SPF indicate a poorer prognosis, guiding adjuvant therapy decisions.
Area of Science:
- Oncology
- Breast Cancer Research
- Prognostic Biomarkers
Background:
- Adjuvant systemic therapy for node-negative breast cancer is best justified in high-risk patients.
- Identifying reliable prognostic factors is crucial for treatment decisions.
Purpose of the Study:
- To evaluate tumor size, histologic grade, ER, ploidy, and S-phase fraction (SPF) as predictors of relapse-free survival (RFS) in node-negative breast cancer.
- To define prognostic groups for better patient stratification.
Main Methods:
- Analysis of RFS in 169 node-negative breast cancer patients.
- Statistical evaluation of tumor size (≤1.0 cm vs. >1.0 cm), histologic grade, ER, PgR, ploidy, and SPF.
- Stratification into prognostic groups based on combined tumor size and SPF.
Main Results:
- Small tumors (≤1.0 cm) showed significantly better RFS (96% at 5 years).
- For tumors >1.0 cm, histologic grade 3 was associated with poorer prognosis (P=.04).
- SPF >10% was the strongest predictor of relapse (5-year RFS 52% vs. 78% for SPF ≤10%).
Conclusions:
- Combined tumor size and SPF effectively stratify node-negative breast cancer patients into distinct prognostic groups.
- These groupings can aid in identifying patients most likely to benefit from adjuvant systemic therapy.